Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 May 2021 | Story Dr Nitha Ramnath
Frikkie Meintjes

University of the Free State alumni have an impact on a diverse range of fields, locally and internationally. They are sought after in private and public companies, leading and working in some of the top companies and organisations. One such individual is Frikkie Meintjes, Head of Global HR at Greenpeace International. 

Reconnecting alumni with the UFS and their university experience, François van Schalkwyk and Keenan Carelse, UFS alumni leading the university’s United Kingdom Alumni Chapter, have put their voices together to produce and direct a podcast series, Voices from the Free State. The podcasts are authentic conversations – providing an opportunity for the university to understand and learn about the experiences of its alumni and to celebrate the diversity and touchpoints that unite them. As part of the series, featured alumni such as Frikkie Meintjes share and reflect on their experiences at the UFS, how it has shaped their lives, and relate why their ongoing association with the UFS is still relevant and important.

Listen to Frikkie Meintjes talk about his UFS experience and connection here: 

About Frikkie Meintjes

Frikkie Meintjes is a senior management professional with extensive experience in strategic and operational leadership and people management, gained over twenty years in complex international organisations. His senior management experience includes being a member of the senior management team of Greenpeace Africa and being appointed Acting Executive Director in 2015/2016 for a period of 11 months during a leadership transition phase.
He is an experienced leader who effectively leads multicultural teams to achieve organisational goals. Frikkie’s notable achievements include harnessing a new team across four offices on the African continent, implementing a new job evaluation and grading system (Hay Group) through collaborative team efforts and a related salary structure for four offices across Africa, establishing a staff representative forum (similar to the Dutch Ondernemingsraad), and ensuring unqualified external audited annual financial statements (after a period of successive failed audits).

Leading teams from around the world

Frikkie is currently the Head of Global HR and manages a team of six HR professionals. His key deliverables include implementing the Global People Strategy and handling HR people or systems-oriented critical incidents at any of the 27 regional and national offices. The position also strengthens the global HR community and uses data to improve the overall organisational effectiveness of HR across the global organisation. In addition, he is responsible for ensuring the alignment of HR strategies and its implementation across the global organisation and provides support and expertise to senior leadership and HR professionals.

Frikkie has also worked as an international development manager in Amsterdam, the Netherlands, where his role ensured the continual growth and development of particular Greenpeace-affiliated national and regional organisations though the provision of strategic support and advice to the organisation’s leadership and by optimising synergies between organisations across the Greenpeace federation in the process of upholding the integrity of the Greenpeace global organisation and movement. The development of the executive director included regular coaching and mentoring. He represented the International Executive Director during local board meetings. Organisations assigned to him included Japan, East Asia (with offices in China, Hong Kong, Taiwan, and Korea), and Southeast Asia (with presences in the Philippines, Indonesia, Thailand, and Malaysia).

Prior to that, he served as the Operations Manager: Office of the Executive Director at Greenpeace International. He was an observer, mentor, and coach on the Future Leadership Programme held in May 2017 in Vienna, Austria, and provided advice to fifteen emerging talents. He was also a member of the Performance, Accountability and Learning (PAL) Steering Committee, advising the global organisation on monitoring and evaluation strategies, policies, and best practices.

Frikkie Meintjies has also worked for World Vision as a support services director, and for Phumani Paper in Johannesburg as an executive director.

The UFS – where it started

He completed his studies at the University of the Free State in the field of Commerce (1990-1996). During his studies, he had been involved in various activities and societies, which included being recognised as Best Residence Committee Member for Cultural Affairs; recognised as the Best Student Association, recognised for the best community engagement programme of a student association; member of the Residence Committee: Cultural Affairs and Liaison, and Chairperson of the Association of Management Sciences. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept